Avatrombopag is an orally active, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Avatrombopag is the active ingredient of these drugs:
Austria Finland Ireland Lithuania Poland
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):